These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 369152)

  • 1. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [DTIC in the therapy of solid tumours (author's transl)].
    Kokron O; Pridun N; Zischinsky W
    Wien Klin Wochenschr; 1978 Dec; 90(24):864-7. PubMed ID: 741753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)].
    Huber H; Grünewald K
    Wien Klin Wochenschr; 1978 Dec; 90(24):861-4. PubMed ID: 369151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunology and therapy of malignant melanoma (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of metastatic malignant melanoma (author's transl)].
    Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
    Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of malignant melanoma--current status].
    Karg C; Garbe C; Orfanos CE
    Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
    Chauvergne J; Clavel B; Klein T; Pommatau E
    Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dimethyl-triazeno-imidazol-carboxamide (DTIC)--a new cytostatic agent].
    Klepp O
    Tidsskr Nor Laegeforen; 1975 Sep; 95(27):1550-1. PubMed ID: 1179374
    [No Abstract]   [Full Text] [Related]  

  • 16. [DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)].
    Lutz D; Waldner R; Höcker P; Baumgartner G
    Wien Klin Wochenschr; 1978 Dec; 90(24):876-7. PubMed ID: 741755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
    Sava G; Giraldi T; Lassiani L; Nisi C
    Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 19. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.